Good morning.
We’ll admit Joel Thickins is not the only one getting a bit weary of his whole saga, but credit where it’s due. Even staring down a conviction and with TPG weighing whether he keeps the top Australian and regional job, its man kept things light in court.
Thickins reportedly assured his lawyer, after a stranger clocked his fragrance, that reeking of cologne beat "smelling like fear”. Still, we’ll all be watching for TPG’s verdict on the "broader path forward”.
| ▼ | ASX 200 | 8,779 | -0.51% |
| ▲ | ASX futures | 8,783 | +0.08% |
| ▲ | S&P 500 | 7,499 | +0.79% |
| ▲ | NASDAQ | 26,214 | +1.52% |
| ▲ | AUD/USD | 0.69 | +0.48% |
| ▼ | Bitcoin | 58,771 | -2.65% |
ASX 200 as at market close. Bitcoin in USD.
Market movers
Shares in Rett syndrome drug developer Neuren Pharmaceuticals rose Tuesday for a second straight session, extending a rally that began Monday with a 36.1% surge. The gains followed the European Medicines Agency’s decision to reverse its earlier position and recommend EU authorisation of Neuren’s drug Daybue.
Fragrant offence